Swiss-based global biopharmaceutical company Debiopharm Group will break up partnership with Allergan, and will transfer commercialisation licence for Trelstar in the US and Canada.
According to Debipharm’s announcemt, the new agreement, Debiopharm can look for new licensees in North America while Allergan will keep commercial efforts to promote Trelstar and respond to patients’ needs until new partners are secured.
Allergan will be actively supporting Debiopharm in the transfer to the new licensees, and in the meantime will continue its current commercialization activities for Trelstar. Both Debiopharm and Allergan intend to provide undisrupted access to Trelstar for patients and providers, Debiopharm’s statement reads.
“We are now looking for new partners with a strong footprint in urology to continue to bring Trelstar to the patients. We thank Allergan for supporting a smooth transition with our new partner in both the US and Canada,” said Thierry Mauvernay, President & Delegate of the Board, Debiopharm Group.